Global Type 1 Diabetes Market 2016-2020

Description: About Type 1 Diabetes Drugs

Diabetes, often referred to as diabetes mellitus, results in high blood glucose levels. Depending on the cause of development, it can be divided into three types:

- Type 1 diabetes (or insulin-dependent diabetes mellitus): The pancreas do not produce the required amount of insulin in the body, leading to high blood glucose levels.
- Type 2 diabetes (non-insulin-dependent diabetes mellitus): In this condition, though the body produces the required amount of insulin, the cells do not respond to it. This results in a high glucose level in the body.
- Gestational diabetes: This condition occurs in pregnant women without any history of diabetes.

Type 1 diabetes is an autoimmune disorder characterized by high blood glucose levels. In this condition, the immune system is activated against insulin-producing cells. This condition hampers the body's ability to produce insulin and disrupts blood glucose homeostasis. Type 1 diabetes differs from a more prevalent form of diabetes mellitus, type 2 diabetes, wherein the insulin is produced inside the body. Type 1 diabetes accounts for only 5%-15% of the total diabetes cases. As the disease is more prevalent among children and adolescents aged 0-15 years, it was earlier known as juvenile diabetes. Type 1 diabetes management relies on providing symptomatic relief and improving the quality of life of people.

The analysts forecast the global type 1 diabetes drugs market to grow at a CAGR of 8.05% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global type 1 diabetes drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs and biosimilars used to treat and prevent type 1 diabetes.

The market is divided into the following segments based on geography:

- Americas
- APAC
- EMEA

The report, Global Type 1 Diabetes Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

- Eli Lilly and Company
- Novo Nordisk A/S
- Sanofi SA

Other prominent vendors

- Adocia
- Astellas Pharma
- AstraZeneca
- Baxalta
- Baxalta
- Biocon
- Biodel
- Boehringer Ingelheim
- CureDM
- Dance Biopharm
- Diamyd Therapeutics AB
- Diasome Pharmaceuticals
- DiaVac
- Exsulin
- Gan & Lee Pharmaceuticals
- Generex Biotechnology
- GlaxoSmithKline
- ILTOO Pharma
- Intrexon
- Islet Sciences
- Kamada
- Kotobuki Pharmaceutical
- Lexicon Pharmaceuticals
- Living Cell Technologie
- MacroGenics
- MannKind Pharmaceuticals
- Merck
- Merrion Pharmaceutical
- Oramed Pharmaceuticals
- Osiris Therapeutics
- Perle Biosciences
- Pfizer
- REGiMMUNE
- Strongbridge Biopharma
- Toleranzia
- Tolerio
- Xeris Pharmaceuticals
- XOMA

Market drivers
- Increase in prevalence of type 1 diabetes
- For a full, detailed list, view the full report

Market challenges
- Poor storage conditions and distribution policies for insulin
- For a full, detailed list, view the full report

Market trends
- Awareness programs and initiatives
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Contents:

PART 01: Executive summary
- Highlights

PART 02: Scope of the report
- Market overview
- Top-vendor offerings
PART 03: Market research methodology
   - Research methodology
   - Economic indicators

PART 04: Introduction
   - Key market highlights
   - Key buying criteria

PART 05: Disease overview
   - Introduction
   - Risk factors
   - Diagnosis
   - Management
   - Epidemiology
   - Economic burden

PART 06: Insulin: An overview
   - Product portfolio
   - Global human insulin market

PART 07: Pipeline analysis
   - Faster-acting insulin aspart (NN1218)
   - Farxiga/Forxiga
   - SAR342434
   - NN9211
   - LY2605541
   - Sotagliflozin
   - MK-1293
   - PRL001
   - Otelixizumab

PART 08: Reimbursement scenario in US

PART 09: Market landscape
   - Global diabetes drugs market
   - Global type 1 diabetes drugs market
   - Five forces analysis

PART 10: Market segmentation by drug class
   - Insulin
   - Others

PART 11: Geographical segmentation
   - Type 1 diabetes drugs market in Americas
   - Type 1 diabetes drugs market in EMEA
   - Type 1 diabetes drugs market in APAC

PART 12: Market drivers
   - Increase in prevalence of type 1 diabetes
   - Advances in insulin delivery technology
   - Rise in price of insulin drugs
   - Stringent regulatory conditions for biosimilar drugs
   - Promising drug pipeline

PART 13: Impact of drivers

PART 14: Market challenges
   - Side effects of current therapies
   - Fierce market competition
   - Poor storage conditions and distribution policies for insulin
   - Gap in nation-level diabetes management plans
   - Rising concerns in scientific community
PART 15: Impact of drivers and challenges

PART 16: Market trends
- Development of drugs with novel mechanisms
- Awareness programs and initiatives
- Focus on emerging markets
- Increase in academia-industry collaboration

PART 17: Vendor landscape
- Competitive scenario
- Market analysis 2015
- Novo Nordisk
- Sanofi
- Eli Lilly
- Other prominent vendors

PART 18: Appendix
- List of abbreviations

PART 19: About the Author

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for type 1 diabetes drugs
Exhibit 03: Diagnostic test for diabetes based on blood sugar levels
Exhibit 04: Diagnostic test for diabetes based on glycated hemoglobin levels
Exhibit 05: Global human insulin market 2015-2020 ($ billions)
Exhibit 06: Pipeline portfolio: Global type 1 diabetes drugs market
Exhibit 07: Global diabetes drugs market by type of disease prevalence 2015
Exhibit 08: Top-selling diabetes drugs based on sales 2014 ($ billions)
Exhibit 09: Market share of global diabetes drugs in global pharmaceutical drugs market 2015
Exhibit 10: Global diabetes drugs market 2015-2020 ($ billions)
Exhibit 11: Market share analysis of vendors in global diabetes drugs market 2015
Exhibit 12: Global type 1 diabetes drugs market 2015-2020 ($ billions)
Exhibit 13: Five forces analysis
Exhibit 14: Segmentation of type 1 diabetes drugs market by drug class
Exhibit 15: Estimated market share of global type 1 diabetes drugs market by drug class 2020
Exhibit 16: Segmentation of global type 1 diabetes drugs market based on geography 2015
Exhibit 17: Type 1 diabetes drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 18: Global type 1 diabetes drugs market by geography 2015-2020
Exhibit 19: Type 1 diabetes drugs market in Americas 2015-2020 ($ billions)
Exhibit 20: Type 1 diabetes drugs market in EMEA 2015-2020 ($ billions)
Exhibit 21: Type 1 diabetes drugs market in APAC 2015-2020 ($ billions)
Exhibit 22: Global type 1 diabetes drugs market: YoY growth and revenue based on geography 2015-2020
Exhibit 23: Impact of drivers
Exhibit 24: Impact of drivers and challenges
Exhibit 25: Revenues from sales of major products in type 1 diabetes market 2012-2014 ($ billions)
Exhibit 26: Novo Nordisk: Business segmentation by revenue 2015
Exhibit 27: Novo Nordisk: R&D expenditure 2015
Exhibit 28: Novo Nordisk: YoY revenue and growth rate generated from net product sales of human insulins 2012-2015 ($ billions)
Exhibit 29: Novo Nordisk: YoY revenue and growth rate generated from net product sales of Levemir 2012-2015 ($ billions)
Exhibit 30: Novo Nordisk: YoY revenue and growth rate of NovoRapid/NovoLog 2012-2015 ($ billions)
Exhibit 31: Novo Nordisk: Geographical split of revenues of NovoRapid/NovoLog, 2015
Exhibit 32: Novo Nordisk: YoY revenue and growth rate of NovoMix/NovoLog Mix 2012-2015 ($ billions)
Exhibit 33: Novo Nordisk: Geographical split of revenues of NovoMix/NovoLog Mix, 2015
Exhibit 34: Novo Nordisk: YoY revenue and growth rate generated from net product sales of new-generation insulins 2013-2015 ($ millions)
Exhibit 35: Novo Nordisk: Key takeaways
Exhibit 36: Sanofi: Business segmentation by revenue 2015
Exhibit 37: Sanofi: YoY revenue and growth rate of Lantus 2013-2015 ($ billions)
Exhibit 38: Sanofi: Lantus geographical segmentation by revenue 2015
Exhibit 39: Sanofi: YoY revenue and growth rate of Apidra 2013-2015 ($ millions)
Exhibit 40: Sanofi: YoY revenue and growth rate of Insuman 2013-2015 ($ millions)
Exhibit 41: Sanofi: Key takeaways
Exhibit 42: Eli Lilly: YoY revenue and growth rate of Humalog 2013-2015 ($ billions)
Exhibit 43: Eli Lilly: YoY revenue and growth rate of Humulin 2013-2015 ($ billions)
Exhibit 44: Eli Lilly: Key takeaways

Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global Type 1 Diabetes Market 2016-2020
Web Address: http://www.researchandmarkets.com/reports/3642700/
Office Code: SCBRKSOD

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td></td>
<td>USD 2500</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users:</td>
<td></td>
<td>USD 3000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td></td>
<td>USD 10000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  
Mr  [ ]  Mrs  [ ]  Dr  [ ]  Miss  [ ]  Ms  [ ]  Prof  [ ]

First Name: ______________________  Last Name: ______________________

Email Address: * ______________________

Job Title: ______________________

Organisation: ______________________

Address: ______________________

City: ______________________

Postal / Zip Code: ______________________

Country: ______________________

Phone Number: ______________________

Fax Number: ______________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World